TABLE 2

Summary of PET-Based and CT-Based Response Assessment Criteria for Immunotherapy Response Evaluation

18F-FDG PET/CT– based criteriaCT-based criteria
ResponsePERCISTimPERCISTResponseRECISTiRECIST
 PMD >30% relative increase and >0.8 absolute increase in SULpeak of hottest lesion or unequivocal progression of 18F-FDG–avid nontarget lesion or appearance of new 18F-FDG–avid lesion Defined only by increase in sum of SULpeak of 5 lesions by 30% PD ≥20% increase in sum of diameters of TLs or unequivocal progression of NL or appearance of new lesion iUPD: ≥20% of sum of longest diameters compared with nadir (minimum, 5 mm) or progression of nontarget lesions or new lesion; confirmation of progression recommended at minimum of 4 wk after first iUPD assessment
iCPD: increased size of target or nontarget lesions; increase in sum of new target lesions > 5 mm; progression of new nontarget lesions; appearance of another new lesion
 SMD Not meeting criteria for CMR, PMR, or PMD Not meeting definitions for CMR, PMR, or PMD StD Neither sufficient TR nor sufficient TG to qualify for PR or PD Neither sufficient TR nor sufficient TG to qualify for PR or PD
PMR>30% relative decrease and >0.8 absolute decrease in SULpeak of hottest lesionDecrease in sum of SULpeak by at least 30%PR≥30% decrease in SoDs of TLs; NLs may persist but not unequivocally progress≥30% decrease in SoDs of TLs; NLs may persist but not unequivocally progress
 CMR Complete resolution of 18F-FDG uptake within measurable target lesion and disappearance of all other lesions to background blood-pool levels Resolution of all malignant lesions; nominally assigned SULpeak of zero for quantitative analysis CR Disappearance of all TLs and NLs; all LNs < 10 mm on short axis Disappearance of all TLs and NLs; all LNs < 10 mm on short axis
  • LN = lymph node; NL = nontarget lesion; TG = tumor growth; TL = target lesion; TR = tumor regression; iUPD = unconfirmed PD; iCPD = confirmed PD; SoD = sum of diameters.